Ichthyosis
1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
GaldermaTX - Dallas
1 programDefining the Skin and Blood Biomarkers of IchthyosisN/A1 trial
Active Trials
Vanda PharmaceuticalsWASHINGTON, DC
1 programImsidolimabPHASE_2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Leo PharmaTMB-001
Vanda PharmaceuticalsImsidolimab
GaldermaDefining the Skin and Blood Biomarkers of Ichthyosis
Clinical Trials (3)
Total enrollment: 358 patients across 3 trials
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
Start: Jun 2022Est. completion: Sep 2024153 patients
Phase 3Completed
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Start: Jan 2021Est. completion: Nov 20215 patients
Phase 2Terminated
Defining the Skin and Blood Biomarkers of Ichthyosis
Start: Jan 2018Est. completion: Dec 2027200 patients
N/AEnrolling By Invitation
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.